Sept 28 -- The National Institutes of Health (NIH) requests for information (RFI) on the use of Real-World Data (RWD), including Electronic Health Records, for Biomedical and Behavioral Research. The NIH RFI is open for public comment. To assure consideration, your response must be received by December 14, 2023, 11:59 p.m. (ET).
The National Institutes of Health (NIH) is requesting public comment on the use of Real World Data (RWD) for NIH supported biomedical and behavioral research, including opportunities for leveraging the benefits of RWD and strategies for responsible use. NIH also seeks to better understand community perspectives on the potential value and constraints—including scientific, administrative, legal, business, and bioethical—for the greater use of RWD in NIH-sponsored biomedical and behavioral research.
Researchers are increasingly using data collected in real-world settings to augment traditional research studies, as well as develop more effective treatments and interventions for patients. These “real-world data (RWD)”, defined by the U.S. Food and Drug Administration, are data relating to patient health status and/or the delivery of health care routinely collected from a variety of sources. Examples of RWD include data derived from electronic health records, medical claims data, data from product or disease registries, and data gathered from other sources (such as digital health technologies) that can inform on health status. While these data hold tremendous promise for biomedical and behavioral research, they can be collected from a variety of sources through multiple mechanisms, creating challenges for researchers and questions for those whose data are being shared.
Importantly, NIH is committed to ensuring participant privacy and autonomy are protected in all NIH-supported research. As NIH establishes health-related research data platforms that include access to RWD, NIH continues to prioritize maximizing data access while upholding participant preferences regarding the collection and use of their data. Most recently, through the Advisory Committee to the NIH Director, (
https://www.acd.od.nih.gov/index.html), NIH staff met with stakeholders to better understand their perspectives on benefits and risks of combining and using human datasets, particularly from disparate sources (e.g., research and non-research settings) and how their data should be used in biomedical and behavioral research. NIH will continue working to incorporate these perspectives in its research studies to build trust and honor participant preferences. Input requested on this RFI will be used to inform NIH's continuing development of guidance on the use of RWD for research and assist in the planning for appropriate mechanisms and programs for research with RWD.
NIH is requesting public comment on the use of RWD for NIH-supported biomedical and behavioral research, including opportunities for leveraging the benefits of RWD and strategies for its responsible use. NIH also seeks to better understand community perspectives on the potential value and constraints—including scientific, administrative, legal, business, and bioethical—for the increased use of RWD in biomedical and behavioral research.
Response to this RFI is voluntary and may be submitted anonymously. Respondents are free to address any or all topics listed below, as well as other relevant topics, for NIH's consideration.
1. Scientific value and quality considerations for collection, use, and sharing of RWD in biomedical and behavioral research -- NIH seeks broad input on how RWD is acquired and used in NIH-funded research, the demonstrated and anticipated value of RWD in research, and opportunities and challenges related to data standards and quality, representativeness, and potential biases for using RWD in research. Additionally, NIH is seeking information on:
(a) Biomedical and behavioral research questions that could be investigated using RWD, including novel unanticipated insights that have been enabled by using RWD in research.
(b) Barriers to using RWD in research, such as bias, underrepresentation of populations in data, and technical issues of data harmonization and linkage.
2. Using RWD as part of the scientific paradigm, including open science, scientific rigor and reproducibility, and team science -- NIH seeks broad input on the opportunities and challenges related to using RWD as part of the scientific process.
(a) Approaches or methods for using RWD in collaborative teams and ensuring reproducibility.
(b) How do researchers assess the validation and verification of RWD data that is used in research.
(c) Appropriate open science practices and use of the FAIR principles (
https://www.nature.com/articles/sdata201618) for research using RWD and approaches for maximizing appropriate data sharing when expected by the NIH Policy for Data Management and Sharing (
https://sharing.nih.gov/data-management-and-sharing-policy) or other policies.
3. Administrative and logistical considerations for collecting, using, and sharing RWD for biomedical and behavioral research -- NIH seeks broad input on the opportunities and challenges related to the process of acquiring, using, and making RWD available for biomedical and behavioral research, including:
(a) Pros and cons of various approaches for obtaining RWD through algorithms, purchasing RWD through trusted parties, accessing RWD through secure enclaves, etc.
(b) Considerations regarding licensing, costs, third party involvement, and restrictions for data use and sharing.
(c) Availability/utility of emerging de-identification technologies and data storage/sharing considerations.
4. Ethical considerations for using RWD for biomedical and behavioral research -- NIH seeks broad input on the opportunities and challenges related to potential bioethical issues regarding the collection, use, and sharing of RWD, including:
(a) Strategies for protecting participant privacy and autonomy.
(b) Potential re-identification risks for RWD, including the technical feasibility of re-identifying linked data and the possibility of anonymity for patients, research participants, and their families.
(c) Ethical implications of data as a “commodity”, in terms of buying and selling personal health data.
FRN:
https://www.federalregister.gov/d/2023-21239